Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M36,667Revenue $M16,671Net Margin (%)14.2Altman Z-Score3.2
Enterprise Value $M43,997EPS $4.6Operating Margin %15.9Piotroski F-Score5
P/E(ttm)15.7Beneish M-Score-2.7Pre-tax Margin (%)14.2Higher ROA y-yN
Price/Book5.110-y EBITDA Growth Rate %10.9Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.25-y EBITDA Growth Rate %5.5Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow49.1y-y EBITDA Growth Rate %-2.3ROA % (ttm)9.3Higher Current Ratio y-yN
Dividend Yield %3.1PEG3.6ROE % (ttm)28.8Less Shares Outstanding y-yY
Payout Ratio %61.0Shares Outstanding M544ROIC % (ttm)14.2Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXRichard Pzena 2015-03-31 Add0.41%$67 - $73.31
($69.8)
$ 67.37-3%Add 27.49%5,028,418
BAXJoel Greenblatt 2015-03-31 Add0.13%$67 - $73.31
($69.8)
$ 67.37-3%Add 4622.98%244,934
BAXFirst Eagle Investment 2015-03-31 Reduce-0.12%$67 - $73.31
($69.8)
$ 67.37-3%Reduce 99.84%1,100
BAXDavid Dreman 2015-03-31 Add0.03%$67 - $73.31
($69.8)
$ 67.37-3%Add 124.77%7,876
BAXTweedy Browne 2015-03-31 Reduce-0.01%$67 - $73.31
($69.8)
$ 67.37-3%Reduce 0.29%2,564,814
BAXJohn Keeley 2015-03-31 Add0.01%$67 - $73.31
($69.8)
$ 67.37-3%Add 26.95%53,460
BAXCharles Brandes 2015-03-31 Reduce-0.01%$67 - $73.31
($69.8)
$ 67.37-3%Reduce 3.40%229,981
BAXMario Gabelli 2015-03-31 Reduce$67 - $73.31
($69.8)
$ 67.37-3%Reduce 4.66%164,850
BAXRichard Pzena 2014-12-31 Buy 1.5%$67.24 - $74.7
($71.71)
$ 67.37-6%New holding3,944,140
BAXBill Nygren 2014-12-31 Sold Out -0.75%$67.24 - $74.7
($71.74)
$ 67.37-6%Sold Out0
BAXFirst Eagle Investment 2014-12-31 Reduce-0.06%$67.24 - $74.7
($71.71)
$ 67.37-6%Reduce 32.14%676,637
BAXMario Gabelli 2014-12-31 Reduce-0.02%$67.24 - $74.7
($71.71)
$ 67.37-6%Reduce 23.14%172,900
BAXJoel Greenblatt 2014-12-31 Buy $67.24 - $74.7
($71.74)
$ 67.37-6%New holding5,186
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$71.28 - $77
($74.81)
$ 67.37-10%Sold Out0
BAXDavid Dreman 2014-09-30 Buy 0.02%$71.28 - $77
($74.81)
$ 67.37-10%New holding3,397
BAXFirst Eagle Investment 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 67.37-9%Add 90872.40%1,000,696
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 67.37-9%Sold Out0
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 67.37-9%New holding37,150
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 67.37-9%Sold Out0
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$66.49 - $72.85
($68.75)
$ 67.37-2%Reduce 77.96%531,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STROUCKEN ALBERT P LDirector 2015-04-27Sell4,830$71.06-4.95view
STORM KORNELIS J.Director 2015-04-27Sell4,830$71.05-4.94view
GAVIN JAMES R IIIDirector 2015-04-27Sell4,830$71.06-4.95view
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-5.3view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-9.83view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-12.26view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-12.08view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-11.13view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-9.23view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-10.28view

Press Releases about BAX :

    Quarterly/Annual Reports about BAX:

    News about BAX:

    Articles On GuruFocus.com
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
    Live Off Your Monthly Dividend Portfolio Mar 19 2015 
    Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
    To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
    Best Stock Pick For Long Term Investors Feb 10 2015 
    Richard Pzena's New Buys Feb 09 2015 
    Richard Pzena's 5 New Q4 Stock Buys Feb 06 2015 
    Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
    Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
    I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 

    More From Other Websites
    Why Baxter May Be Very Undervalued Into Breakup May 21 2015
    Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin... May 21 2015
    Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin... May 21 2015
    9:00 am Baxter BioScience files for European approval of investigational 20% subcutaneous immune... May 21 2015
    Baxter's Spain Plant FDA-Approved for Saline Production - Analyst Blog May 20 2015
    Goldman Sachs Just Endorsed These 10 Dividend Growth Stocks May 20 2015
    Novo Nordisk, Baxter clash over haemophilia drug patent May 20 2015
    Novo Nordisk rejects Baxter patent claim over Novoeight May 20 2015
    Baxter, Baxalta Provide Business Outlook as Spin-Off Nears - Analyst Blog May 19 2015
    Baxter and Baxalta Highlight Business Strategies at Investor Conferences May 18 2015
    Baxter and Baxalta Highlight Business Strategies at Investor Conferences May 18 2015
    Baxter Receives U.S. FDA Approval for 0.9% Sodium Chloride Injection, USP from Sabinanigo, Spain,... May 15 2015
    Baxter Receives U.S. FDA Approval for 0.9% Sodium Chloride Injection, USP from Sabinanigo, Spain,... May 15 2015
    Baxter Boosts Oncology Pipeline With $900M Cross-Border Deal May 14 2015
    Baxter Looks to Expand in Oncology; Acquires New Portfolio - Analyst Blog May 13 2015
    BAXTER INTERNATIONAL INC Financials May 13 2015
    Economists Anthony Culyer and Alan Maynard Named Co-Recipients of the 2015 William B. Graham Prize... May 13 2015
    Economists Anthony Culyer and Alan Maynard Named Co-Recipients of the 2015 William B. Graham Prize... May 13 2015
    Moody's: Baxter's Acquisition of Oncaspar is Credit Negative May 12 2015
    REUTERS BUSINESS NEWS SCHEDULE 1830 GMT/2:30 PM ET May 12 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Sww
    ReplySww - 10 months ago
    Bax medical devices revenue ~9b, bio science ~7b
    using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

    72 * (1 + 16/39) = 99

    72 is current stock price, with an upside of around 35%

    so my guess is BAX may be able to sell for around 90 after spin-off.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK